Any current/future new fundraising through debt or equity?

The transcript does not mention any specific plans for current or future fundraising through debt or equity. There is no direct reference to raising capital via new debt or equity offerings. The focus is more on operational growth, cost reduction, and inorganic acquisitions to add hospital beds. Existing investments and cost controls are highlighted, but no funding rounds or capital raising activities are discussed. The company is aiming for breakeven and reducing losses, indicating a focus on internal cash flow management rather than external fundraising at this time.

Future growth expectations in sales/revenue/volumes?

Apollo 24/7 aims to double GMV from FY23 levels, targeting INR 3,000 crore revenue in FY24, primarily driven by pharmacy sales, while maintaining marketing spend. Hospital services expect to grow revenue by 13%-15% with EBITDA growth higher due to operating leverage and cost cuts. Hospital occupancy targeted to increase to 70% by end of FY24, unlocking margin improvements. Addition of 2,000 new hospital beds planned by 2027, with around 700 beds added annually post FY24. Offline pharmacy stores expansion continues with 500-600 new stores planned next year. Diagnostics division aims for 35%-40%

Future growth expectations in earnings/operating earnings/profits/EPS?

Healthcare Services EBITDA expected to grow by around 15% in FY24, driven by higher occupancy and cost efficiencies. Occupancy across hospitals targeted to improve to 70% by end FY24 from 64% currently, which should disproportionately increase profitability. EBITDA margin in Healthcare Services projected to improve by an additional 100 basis points beyond the recent 249 basis points increase. Apollo 24/7 aims to double its GMV in FY24 vs FY23 level, targeting breakeven at an entity level by Q4 FY24. Expenses as a percentage of GMV in Apollo 24/7 planned to reduce from 39% (FY23 end) to

Apollo HospitalsQ4 FY23Healthcare Services

Apollo Hospitals Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹8,836P/E: 60.4Market Cap: ₹1.3L CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Apollo 24/7 aims to double GMV from FY23 levels, targeting INR 3,000 crore revenue in FY24, primarily driven by pharmacy sales, while maintaining marketing spend.
Hospital services expect to grow revenue by 13%-15% with EBITDA growth higher due to operating leverage and cost cuts.
Hospital occupancy targeted to increase to 70% by end of FY24, unlocking margin improvements.
Addition of 2,000 new hospital beds planned by 2027, with around 700 beds added annually post FY24.
Offline pharmacy stores expansion continues with 500-600 new stores planned next year.
Diagnostics division aims for 35%-40% growth annually, targeting margin improvement from 7.5% toward 10%-15%.
IVF and Cradle segments expected to grow utilization without significant new centers, contributing positively to margins.
Apollo 24/7 platform has shown 266% growth in transactions year-on-year, reflecting increasing active and repeat users.

Margin guidance

Category 3

Healthcare Services EBITDA expected to grow by around 15% in FY24, driven by higher occupancy and cost efficiencies.
Occupancy across hospitals targeted to improve to 70% by end FY24 from 64% currently, which should disproportionately increase profitability.
EBITDA margin in Healthcare Services projected to improve by an additional 100 basis points beyond the recent 249 basis points increase.
Apollo 24/7 aims to double its GMV in FY24 vs FY23 level, targeting breakeven at an entity level by Q4 FY24.
Expenses as a percentage of GMV in Apollo 24/7 planned to reduce from 39% (FY23 end) to 20-23% in FY24, improving operating leverage.
Back-end pharmacy EBITDA margin expected to stabilize around 7.5% to 8% by end FY24 after front-end store expansion costs normalize.
Diagnostics division targets margin expansion from 7.5% to 10-12% and potentially 15% with ongoing investments.
Overall, strategic cost reductions and higher operating leverage form the basis for improved earnings growth and profitability.

See what Apollo Hospitals management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any specific plans for current or future fundraising through debt or equity.
There is no direct reference to raising capital via new debt or equity offerings.
The focus is more on operational growth, cost reduction, and inorganic acquisitions to add hospital beds.
Existing investments and cost controls are highlighted, but no funding rounds or capital raising activities are discussed.
The company is aiming for breakeven and reducing losses, indicating a focus on internal cash flow management rather than external fundraising at this time.

Order book

The transcript of the AHEL Q4 FY23 Earnings Call does not provide specific details on the current or expected order book or pending orders. The focus is mainly on hospital bed additions, occupancy targets, store expansion, revenue growth, and margins across different business segments. - No explicit mention of current order book or pending orders. - Discussed ongoing and planned bed additions (2,000 beds by 2027). - Expansion plans in Tier 1 cities via new hospitals and acquisitions. - Offline store additions planned at 500-600 stores next year. - Revenue growth guidance, GMV growth, and EBITDA improvements highlighted. - Investments in digital platform Apollo 24/7 and its growth metrics. For precise data on order books or pending orders, please refer to formal company filings or investor presentations beyond this call transcript.

See what Apollo Hospitals management said on order book — free account, 30 seconds.

Capex plans

Yes

- Inorganic expansion plan to add 2,000 beds at an outlay of around INR 3,000 crore over the next four years focused on key metros (Delhi, Chennai, Bangalore, Mumbai, Calcutta, Hyderabad). (Page 3, 6, 14) - Addition of approximately 700 new hospital beds per year starting after FY24; aiming to add a new hospital each year by 2027. (Page 14) - Continued investment in digital platform Apollo 24/7 with no major incremental capex expected beyond one-time tech and product development completed; ongoing investment primarily in digital and clinical intelligence engine (CI). (Page 14) - Focus on brownfield expansions and acquisitions for hospital services growth with new beds largely coming post FY25. (Page 10, 14) - Targeted operational efficiencies and cost reductions rather than large new tech capex in 24/7 in FY24. (Page 14) Overall, capex is focused on hospital bed additions and selective inorganic growth, with controlled tech investments in digital platforms.

Track Apollo Hospitals — get its next earnings analysis in your feed

Margin guidance

Category 3

Healthcare Services EBITDA expected to grow by around 15% in FY24, driven by higher occupancy and cost efficiencies.
Occupancy across hospitals targeted to improve to 70% by end FY24 from 64% currently, which should disproportionately increase profitability.
EBITDA margin in Healthcare Services projected to improve by an additional 100 basis points beyond the recent 249 basis points increase.
Apollo 24/7 aims to double its GMV in FY24 vs FY23 level, targeting breakeven at an entity level by Q4 FY24.
Expenses as a percentage of GMV in Apollo 24/7 planned to reduce from 39% (FY23 end) to 20-23% in FY24, improving operating leverage.
Back-end pharmacy EBITDA margin expected to stabilize around 7.5% to 8% by end FY24 after front-end store expansion costs normalize.
Diagnostics division targets margin expansion from 7.5% to 10-12% and potentially 15% with ongoing investments.
Overall, strategic cost reductions and higher operating leverage form the basis for improved earnings growth and profitability.

Order book

How does Apollo Hospitals rank vs peers in Healthcare Services?

Pro feature

ThisApollo Hospitals

Rev 3Mar 3

See where Apollo Hospitals sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Apollo Hospitals rank in Healthcare Services?

Compare Apollo Hospitals against every Healthcare Services company (Q4 FY23) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Apollo Hospitals's management said in earlier quarters

Others in Healthcare Services this season

Metropolis Healt (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
Health X Platform (Q1 FY27)
July monthly revenue stood at INR 150+ crores, indicating strong growth momentum. Key concall takeaways from Health X Platform Ltd's Q1 FY27 earnings call…
Shalby (Q1 FY27)
Shalby MedTech showed strong revenue growth: ₹47 crores in Q1 FY27, a 53% YoY increase. Key concall takeaways from Shalby Ltd's Q1 FY27 earnings call — and how…
Nephrocare Health Services (Q1 FY27)
International operations contribute around 45% of revenue, reflecting their growing importance in overall growth. Key concall takeaways from Nephrocare Health…

Compare:vs Max Healthcare vs Fortis Health.vs Aster DM Quality

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Apollo Hospitals Q4 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

Margin guidance

Order book

How does Apollo Hospitals rank in Healthcare Services?

Continue your research

What Apollo Hospitals's management said in earlier quarters

Others in Healthcare Services this season